Guillaume Pfefer, PhD, MBA
President and CEO

Dr. Guillaume Pfefer joined Kala in July, 2012 as the company's President and CEO and a member of the board of directors. Dr. Pfefer brings to Kala more than 15 years of experience in the pharmaceutical industry leading commercial, strategic, R&D, and industrial operations. Prior to joining Kala, Dr. Pfefer held a number of ascending leadership positions over a nine-year career at Sanofi Pasteur. He most recently served as General Manager of Sanofi Pasteur Mexico, one of the company's largest worldwide affiliates. His previous positions include Vice President, Global Head of the Sanofi Pasteur's Influenza and Pneumococcal Franchise and Global Head of Corporate Strategy. Prior to his tenure with Sanofi Pasteur, Dr. Pfefer held executive management positions with Aventis and Rhone-Poulenc. Dr. Pfefer holds a Master's degree in Chemical Engineering from the National School for Chemical Engineering (Nancy, France), a PhD in Materials Science from Centre National de la Recherche Scientifique (CNRS), France, and a MBA from the Wharton School at the University of Pennsylvania.

[Back to top]
Guillaume Pfefer, PhD, MBA

Kim Brazzell, PhD
Chief Medical Officer

Dr. Brazzell brings more than 25 years of experience in the ophthalmic pharmaceutical industry to Kala. Previously, he held several executive positions at Inspire Pharmaceuticals, including Executive Vice President, Medical and Scientific Affairs, Executive Vice President and Head, Ophthalmology Business and Senior Vice President of Ophthalmic Research and Development. Prior to joining Inspire, he served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics. He has extensive experience in the discovery and development of multiple successful ophthalmic products including Visudyne®, Zaditor®, RESCULA® and Betoptic S®. In addition to managing the global clinical R&D group for Novartis Ophthalmics, Dr. Brazzell built and managed the U.S.-based R&D group for Ciba Vision Ophthalmics, while serving as their Vice President, R&D, and served as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in pharmacy and a Ph.D. in pharmaceutical sciences from the University of Kentucky.

[Back to top]
Kim Brazzell, PhD, Chief Medical Officer

Hongming Chen, ScD
Executive Vice President of Research

Dr. Hongming Chen joined Kala in January, 2010 and is responsible for Kala's R&D activities. Dr. Chen joined Kala from TransForm Pharmaceuticals, where she was Director of Formulation Development and was responsible for formulation design for drugs and drug/device combinations. Dr. Chen was the first employee at TransForm, and helped to build the company to its acquisition by Johnson & Johnson in 2005 for $230 million. Before joining TransForm, Dr. Chen conducted vaccine delivery research and development at AstraZeneca from 1997 to 2000, and at Merck from 1996 to 1997. In 2014, Mass High Tech named Dr. Chen as one of its 2014 Women to Watch, an annual program recognizing women who are thought leaders and shaping the future of the life sciences industry. Dr. Chen received her B.S. degree in Chemical Engineering from The University of Texas at Austin in 1992, and her Masters and Sc.D. degrees in Chemical Engineering from Massachusetts Institute of Technology in 1995 and 1996, respectively.

[Back to top]
Hongming Chen, ScD

Charlie McDermott
Executive Vice President, Business Development

Mr. McDermott joined Kala in May 2013 as Executive Vice President of Business Development. Mr. McDermott has nearly 20 years of operating experience in the biotechnology and ophthalmology industry. He has taken on positions of increasing responsibility in drug discovery, regulatory affairs and business development. He most recently served as Vice President of Business Development, Eye Care and Drug Delivery at Allergan, an ophthalmic industry leader. During Mr. McDermott’s eight year career at Allergan he served as a leader within the global business development team that was focused on eye care and drug delivery opportunities. Mr. McDermott completed a variety of transactions and partnerships that involved novel platforms (DARPins, PEMs, siRNA, etc.) to commercial products such as Acular™, Acuvail™, Latisse™ and Lastacaft™. Prior to joining Allergan, Mr. McDermott held a variety of business development positions at deCODE Genetics where he had responsibility for growing and integrating service and platform technology businesses. Prior to his business development roles, Mr. McDermott began his career as a research scientist within the angiogenesis pharmacology group at Agouron Pharmaceuticals where he championed the concept of testing potential cancer treatments for angiogenic diseases of the eye. Mr. McDermott earned his MBA at the University of San Diego, a Master’s degree in Molecular, Cellular and Developmental Biology at the University of California at Santa Barbara and his Bachelor of Science in Biochemistry and Molecular Biology from the University of California Santa Cruz.

[Back to top]
Charlie McDermott

Mary Reumuth  
Senior Director, Finance and Corporate Controller

Ms. Reumuth joined Kala in February of 2014 as Senior Director, Finance and Corporate Controller. She brings with her nearly 20 years of diversified finance and accounting experience. Ms. Reumuth was formerly Corporate Controller for Enobia Pharma (acquired by Alexion Pharmaceuticals). Prior to her tenure at Enobia, she spent several years at Genzyme Corporation in Cambridge, MA through the acquisition of ILEX Oncology in San Antonio, Texas. Ms. Reumuth began her career as an auditor with the San Antonio office of Ernst & Young LLP. Ms. Reumuth earned her business degree from Texas A&M University – Corpus Christi and is a Certified Public Accountant.

[Back to top]
Mary Reumuth